CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2

儿童哮喘管理计划继续研究/第 2 阶段

• 批准号: 7377266
• 负责人: Robert Strunk
• 金额: $ 4.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377266
• 关键词: CHILDHOOD; ASTHMA; MANAGEMENT; PROGRAM; CONTINUATION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is for the Childhood Asthma Management Program Continuation Study/Phase 2 (CAMPCS/2), A 3.25 year observational follow-up study of the children enrolled in the Childhood Asthma Management Program (CAMP). CAMP was a multicenter randomized clinical trial designed to determine the effects of three treatments (albuterol alone, albuterol with inhaled corticosteroid (ICS), albuterol with inhaled non-steroid) in 1041 children (randomized at ages 5-13 years) with mild asthma on pulmonary function during a 3.5-5.5 year treatment phase. The cohort has been followed in a 4.5 year observational phase (CAMP Continuation Study, CAMPCS) to determine longer term effects of the treatments on lung and based on national guidelines. CAMPCS/2 is designed to follow the cohort for 4 additional years in to early adulthood, when the patients will be 17-26 years (55% >21 years). Childhood asthma can result in significant lung disease in adulthood and possibly the development of chronic obstructive pulmonary disease (COPD). None of the long-term follow-up studies of childhood asthma have had the close follow-up needed to define determinants of outcomes in inflammatory agents on outcomes.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。本方案适用于儿童哮喘管理计划继续研究/第 2 阶段 (CAMPCS/2)，这是一项针对参加儿童哮喘管理计划 (CAMP) 的儿童进行的 3.25 年观察性随访研究。 CAMP 是一项多中心随机临床试验，旨在确定 1041 名患有轻度哮喘的儿童（随机分组，年龄为 5-13 岁）在 3.5-5.5 年的治疗阶段中三种治疗方法（单独沙丁胺醇、沙丁胺醇联合吸入皮质类固醇 (ICS)、沙丁胺醇联合吸入非类固醇）对肺功能的影响。该队列经过 4.5 年的观察期（CAMP 继续研究，CAMPCS）进行跟踪，以确定治疗对肺部的长期影响，并基于国家指南。 CAMPCS/2 旨在对队列进行额外 4 年的跟踪直至成年早期，届时患者年龄为 17-26 岁（55% >21 岁）。 儿童哮喘可导致成年后出现严重的肺部疾病，并可能发展为慢性阻塞性肺病（COPD）。儿童哮喘的长期随访研究都没有进行必要的密切随访，以确定炎症因子对结局的决定因素。